Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that updated Phase 1/2 clinical data for CRB-701, a next-generation Nectin-4 ADC, will be presented at ASCO 2026 May 29–June 2 in Chicago.
Presentations include an oral session for cervical cancer (May 29) and a poster for HNSCC (May 30). Abstracts post on May 21, 2026. Corbus expects to start a registrational study in second-line HNSCC in mid-2026 and to report CRB-701 plus Keytruda combination data in Q4 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the Last Patient First Visit in its CANYON-1 Phase 1b study of CRB-913 for obesity on April 14, 2026. The 16-week, double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic participants across 20 mg, 40 mg, and 60 mg cohorts.
The study is on track for completion in summer 2026, with participants dosed for three months and monitored one month post-dosing; Phase 1b will build on Phase 1a weight-loss signals.
Corbus Pharmaceuticals (NASDAQ: CRBP) said it reached broad alignment with the FDA on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, enabling potential accelerated approval based on objective response rate (ORR) and potential full approval on overall survival (OS).
Updated monotherapy data will be presented at ASCO 2026; a second-line HNSCC registrational study is expected to start in mid-2026. Chief Medical Officer Dr. Dominic Smethurst will step down June 30, 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will join a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026 at 12:45 pm ET.
Corbus is advancing CRB-913, an oral peripherally restricted CB1 inverse agonist that showed rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study. The company expects to complete a 12-week Phase 1b dose-ranging study (n=240) in summer 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q4 and full‑year 2025 results and a corporate update on March 9, 2026. Key clinical highlights: CRB-701 showed encouraging unconfirmed ORRs (HNSCC 47.6%, cervical 37.5%, bladder 55.6%) and has FDA Fast Track designations. CRB-913 showed 2.9% placebo‑adjusted weight loss at 14 days with favorable GI and neuropsychiatric profiles. Financially, Corbus completed a $75M public offering in Q4 2025 and held $163.3M cash, funding operations into 2028. Anticipated catalysts: CRB-701 and CRB-913 mid‑2026 data readouts; CRB-701 registrational discussions update in Q1 2026.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present a corporate overview and hold investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
The event is virtual on February 25, 2026 with a presentation at 3:20 PM ET; a webcast link will be provided for investors.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for January 15, 2026 at 8:15 a.m. PST / 11:15 a.m. EST. The company will participate in a presentation and one-on-one investor meetings, and a webcast will be available.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Phase 1a single- and multiple-ascending dose results for oral CB1 inverse agonist CRB-913 in obesity on Dec 11, 2025. The study (SAD n=64; MAD n=48) showed no serious treatment-emergent adverse events, minimal GI effects, and stable daily neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7). In a dedicated obese MAD cohort (150 mg QD, n=12), all 9 treated participants lost weight vs 0/3 placebo, with a placebo-adjusted mean weight loss of 2.9% at Day 14 (individual range 1.3%–4.3%). PK supported once-daily oral dosing. A 12-week Phase 1b dose-finding study (CANYON-1) has been initiated, with completion expected in summer 2026. The company will host a conference call and webcast today at 8:00 am ET.
Corbus Pharmaceuticals (NASDAQ: CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of oral CB1 inverse agonist CRB-913 before market open on Thursday, December 11, 2025.
The company will host a conference call and live webcast at 8:00 am ET the same day to review the Phase 1a safety and tolerability data; a replay will be available on the Corbus website.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 2025 results and a corporate update on Nov 12, 2025. The company presented CRB-701 dose-optimization data at ESMO 2025 showing ORRs at 3.6 mg/kg of 47.6% in HNSCC, 37.5% in cervical cancer, and 55.6% in bladder cancer. Corbus plans an FDA meeting in Q1 2026 and expects to start a Phase 2/3 registrational study by mid-2026; CRB-701 has Fast Track designation for HNSCC and metastatic cervical cancer.
The company closed a public offering raising net proceeds of approximately $73.8M (total offering $75M), reporting $104.0M cash on 9/30/25 and stating runway into 2028. CRB-913 SAD/MAD readout and Phase 1b start expected by end of 2025. Q3 net loss was $23.3M versus $13.8M a year earlier.